Background on CAB PrEP

Research:

- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women (NEJM 2021)
- HPTN 083 Study Results (resource page)
  - HPTN 083 Preliminary Study Results (webinar)
  - FAQ (2020)
  - HPTN 083 FAQ_AIDS2020
- HPTN 084 Study Results (resource page)
  - HPTN 084 Primary Study Results (video)
  - FAQ (2020)
  - Open Label Extension FAQ (2021)
- Long-acting injectable PrEP in women: laboratory analysis of HIV infections in HPTN 084 (poster)
- Long Acting Injectable Cabotegravir is Safe and Effective in Preventing HIV Infection in Cisgender Women: Results from HPTN 084 (HIV R4P 2021) (video)
- FDA Approved Apretude Label (2021)

Implementation support materials/tools:

- A Plan for Accelerating Access and Introduction of Injectable CAB for PrEP (2022 report)
- Product Introduction/Implementation Project Planning for Next-Generation PrEP (meeting summary)
- CASPR CAB PrEP (slide decks)
  - For Advocates
  - Testing
  - Product Introduction Basics

Click here to access the July 28, 2022 WHO Guidelines on long-acting injectable cabotegravir for HIV prevention.
- An Advocate’s Primer on Long-Acting Injectable Cabotegravir for PrEP (technical brief)
- Ethical issues in long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial 2021 (The Lancet 2021)
- HPTN 083 Community Webinar (2020)
- HPTN 083: Injectable Cabotegravir vs. Oral Truvada® for Cisgender MSM and Transgender Women (presentation)
- HPTN 083: The HIV Life Cycle Without Cabotegravir (animation)
- HPTN 083: The HIV Life Cycle WITH Cabotegravir (animation)
- Long-Acting Injectable Cabotegravir for PrEP: Understanding Results of HPTN 083 & 084 and key areas for advocacy | AVAC (webinar)
- MOSAIC PREP Learning Network Kick-off: An Exploration of CAB PrEP (webinar)
  o Slides

Helpful pages on PrEPWatch.org
- About Cabotegravir (CAB-LA)
- Evidence and Research for Cabotegravir (CAB-LA)

Other helpful links
- FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention
- Long-Acting Injectable Cabotegravir (AVAC landing page)
- The Years Ahead in Biomedical HIV Prevention Research | AVAC